The state of contemporary molecular diagnostics of colorectal cancer

Wspolczesna Onkologia

Volumn 15, Issue 4, 2011, Pages 229-233

  Zelazowski, Maciej J ^a   Bednarek, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Classification; Colorectal cancer; Diagnostic markers; DNA; Molecular markers; Mutation

Indexed keywords

COMPLEMENTARY DNA; DNA; TUMOR MARKER;

CHROMOSOME ABERRATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DNA CONTENT; DNA MICROARRAY; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; ONCOGENE K RAS; PREDICTION; PROGNOSIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

EID: 80052779415     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2011.24319     Document Type: Review

References (39)

1. Hoff G, Bretthauer M. The science and politics of colorectal cancer screening. PLoS Med 2006; 3: e36.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
3. Soreide K, Nedrebo BS, Knapp JC, Glomsaker TB, Soreide JA, Korner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: Potential implications for the surgical oncologist. Surg Oncol 2009; 18: 31-50.
4. Doolittle BR, Emanuel J, Tuttle C, Costa J. Detection of the mutated K-Ras biomarker in colorectal carcinoma. Exp Mol Pathol 2001; 70: 289-301. (Pubitemid 32607202)
5. Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996; 77 (8 Suppl): 1707-1710. (Pubitemid 26111856)
6. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-27.
7. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448-51. (Pubitemid 9011330)
8. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev Mol Diagn 2008; 8: 277-88. (Pubitemid 351724707)
9. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
10. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-60. (Pubitemid 46874070)
11. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-21. (Pubitemid 24226678)
12. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr., et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 1727-32. (Pubitemid 26399347)
13. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13: 343-6. (Pubitemid 26230501)
14. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-206. (Pubitemid 32319494)
15. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-44. (Pubitemid 40395523)
16. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57. (Pubitemid 28521189)
17. Vicuna B, Benson AB, III. Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Natl Compr Canc Netw 2007; 5: 927-36. (Pubitemid 350069531)
18. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57. (Pubitemid 36859476)
19. Gafa R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89: 2025-37.
20. Soreide K, Slewa A, Stokkeland PJ, van Diermen B, Janssen EA, Soreide JA, et al. Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection. Cancer 2009; 115: 271-82.
21. Banerjea A, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis 2009; 11: 601-8.
22. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-97.
23. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-6.
24. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 7322-9.
25. Yeh CS, Wang JY, Wu CH, Chong IW, Chung FY, Wang YH, et al. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol 2006; 28: 411-20.
26. Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, et al. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg 2007; 246: 1040-6.
27. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005; 229: 115-22.
28. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase- polymerase chain reaction assay. Am J Pathol 2004; 164: 35-42. (Pubitemid 38364587)
29. Webber EM, Lin JS, Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr 2010; 2. pii: RRN1177.
30. Clark-Langone KM, Wu JY, Sangli C, et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007; 8: 279.
31. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-92.
32. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70- gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-87. (Pubitemid 350182954)
33. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003; 22: 663-70.
34. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7. (Pubitemid 28331029)
35. Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer 2008; 113: 2665-70.
36. Parikh AA, Johnson JC, Merchant NB. Genomics and proteomics in predicting cancer outcomes. Surg Oncol Clin N Am 2008; 17: 257-77. (Pubitemid 351423695)
37. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007; 6: 2495-501. (Pubitemid 47122346)
38. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-8.
39. Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32: 247-53.